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An epidemic of infections after video-assisted surgery (1,051 possible cases) caused by rapidly growing
mycobacteria (RGM) and involving 63 hospitals in the state of Rio de Janeiro, Brazil, occurred between August
2006 and July 2007. One hundred ninety-seven cases were confirmed by positive acid-fast staining and/or
culture techniques. Thirty-eight hospitals had cases confirmed by mycobacterial culture, with a total of 148
available isolates recovered from 146 patients. Most (n  144; 97.2%) isolates presented a PRA-hsp65
restriction pattern suggestive of Mycobacterium bolletii or Mycobacterium massiliense. Seventy-four of these
isolates were further identified by hsp65 or rpoB partial sequencing, confirming the species identification asM.
massiliense. Epidemic isolates showed susceptibility to amikacin (MIC at which 90% of the tested isolates are
inhibited [MIC90], 8 g/ml) and clarithromycin (MIC90, 0.25 g/ml) but resistance to ciprofloxacin (MIC90,
>32 g/ml), cefoxitin (MIC90, 128 g/ml), and doxycycline (MIC90, >64 g/ml). Representative epidemic M.
massiliense isolates that were randomly selected, including at least one isolate from each hospital where
confirmed cases were detected, belonged to a single clone, as indicated by the analysis of pulsed-field gel
electrophoresis (PFGE) patterns. They also had the same PFGE pattern as that previously observed in two
outbreaks that occurred in other Brazilian cities; we designated this clone BRA100. All five BRA100 M.
massiliense isolates tested presented consistent tolerance to 2% glutaraldehyde. This is the largest epidemic of
postsurgical infections caused by RGM reported in the literature to date in Brazil.
Outbreaks, pseudooutbreaks, and cases of health-care-asso-
ciated infections caused by rapidly growing mycobacteria
(RGM) have been reported since the first case was described
in 1938 (13). In virtually all nosocomial infections caused by
this group of microorganisms, there were failings in the ster-
ilization processes of solutions, surgical instruments, or medi-
cal devices (13, 14, 45). Recent publications indicate an
increasing number of infections secondary to breast augmen-
tation and video-assisted surgeries (7, 9, 19, 23, 25, 40–43).
The growing number of cases and reports may be due, at
least in part, to the well-known tolerance to alkaline glutaral-
dehyde among Mycobacterium chelonae-Mycobacterium absces-
sus group isolates and to the low susceptibility to high-level
disinfectants (20, 22, 39).
Outbreaks of RGM infections unrelated to medical proce-
dures also can occur and usually are associated with exposure
to recreational water containing a large number of bacteria
and inadequate chlorination (15, 44), highlighting the ubiquity
of these organisms in the environment. In fact, RGM have
been recovered from many different environmental sources,
including soil and water distribution systems (8, 45). RGM are
considered opportunistic pathogens and can cause chronic
lung disease, particularly the species included in the M. chelo-
nae-M. abscessus group (8, 46).
M. chelonae-M. abscessus group taxonomy has undergone
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several updates due to the discrimination of new species by
sequencing multiple housekeeping genes and, to a lesser ex-
tent, by the evaluation of phenotypic characteristics. Mycobac-
terium bolletii and Mycobacterium massiliense are newly pro-
posed species that are closely related to M. abscessus and M.
chelonae, and consequently they should be considered part of
the same group (1, 4). The species M. massiliense was proposed
in 2004 based on nonconventional phenotypic characterization
and genotypic studies of two isolates recovered from sputum
and bronchoalveolar fluid from a patient in Marseille, France
(4). Following the original description, reports from different
areas of the world have described the occurrence of this spe-
cies both in culture collections previously classified as M. ab-
scessus and as the cause of invasive opportunistic infections
and outbreaks (9, 18, 34, 38, 40).
In Brazil, outbreaks caused by RGM have been detected
since 1998, mainly in the cities of Rio de Janeiro and Sa˜o
Paulo. Eight outbreaks following laser in situ keratomileusis
(surgery for myopia correction), mesotherapy sessions (intra-
dermal injections), or breast implants have been described,
most of them associated with species belonging to the M.
chelonae-M. abscessus group. (16, 30–32). Recently, two out-
breaks of surgical-site infection following video-assisted sur-
geries were reported in Brazil (9, 40).
Since August 2006, a large number of surgical wound infec-
tions caused by RGM following video-assisted surgery have
been diagnosed in the state of Rio de Janeiro, in the southeast
region of Brazil. From August 2006 to July 2007, more than
1,000 suspected cases were reported to the Secretary of Health
of the Rio de Janeiro state.
The aim of this work was to define species identification,
antimicrobial and glutaraldehyde susceptibility patterns, and
the clonality of representative mycobacterial isolates recovered
from postsurgery wound infections during the epidemic.
MATERIALS AND METHODS
Case definition. A possible case was defined as a patient who submitted to
video-assisted surgery from August 2006 to July 2007 in the state of Rio de
Janeiro, Brazil, presenting persistent inflammation signs at the surgical incision
site and who had not responded to standard antimicrobial therapy. A probable
case was defined as a patient that fulfilled the possible case definition and had
granulomas in tissue obtained from the surgical wound or surrounding structures
or a positive acid-fast staining but negative culture for mycobacteria. A con-
firmed case was defined as a patient that fulfilled the possible case definition and
had a positive culture for mycobacteria in a clinical sample collected from the
surgical wound or surrounding tissues.
Primary isolation of mycobacteria from clinical samples. Tissue fragments
and secretions were obtained after biopsy or needle aspiration procedures, re-
spectively, and processed for baciloscopy and culture at local clinical laboratories
(24). These were inoculated onto 5% sheep blood agar and chocolate agar,
Lowenstein-Jensen (LJ) slants, and in some laboratories, also in mycobacteria
growth indicator tube (MGIT) broth (Becton-Dickinson, Franklin Lakes, NJ).
Phenotypic tests. All isolates were tested for growth rate, pigment production,
and acid fastness as described elsewhere (24).
Outbreak strains, unrelated controls, and environmental isolate. RGM
strains from previously reported outbreaks of surgical wound infections that
occurred in Brazil in Bele´m city (F1832) and Goiaˆnia city (F1334 and F1345),
one epidemiologically unrelated isolate (CRM-0270), and the M. massiliense type
strain CIP108297 were used as unrelated controls. The isolate CRM-0270 was
recovered in 2007 from a sputum sample collected from a patient who lived in the
city of Rio de Janeiro who had not previously submitted to bronchoscopy. One
isolate (CRM-0029), recovered from a trocar used in a cholecystectomy per-
formed in hospital H18 during the epidemic period, also was included for com-
parison purposes.
PRA-hsp65. All 146 isolates were analyzed initially using the PCR-restriction
enzyme analysis of the hsp65 gene (PRA-hsp65), as previously described by
Telenti et al. (36) and Ringuet et al. (28), with minor modifications. In brief, a
loopfull of recent growth on LJ was suspended in 70 l of 1 Tris-EDTA (TE),
boiled for 10 min, and frozen at 20°C. Amplification was carried out with the
primers Tb11 (5-ACC AAC GAT GGT GTG TCC AT-3) and Tb12 (5-CTT
GTC GAA CCG CAT ACC CT-3). The PCR mixture consisted of 50 mM KCl,
10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 1% formamide, 200 M each de-
oxynucleoside triphosphate (dNTP), 0.5 M primers, 1.25 U Platinum Taq poly-
merase (Invitrogen Life Technologies Brazil, Sa˜o Paulo, Brazil), and 5 l of
bacterial lysate. Amplification was achieved with a GeneAmp PCR system 2400
(Perkin-Elmer, Branchburg, NJ) under the following conditions: 45 cycles of
94°C for 1 min, 60°C for 1 min, and 72°C for 1 min, with a final extension step at
72°C for 10 min. Amplicons were digested with either BstEII (Promega Corpo-
ration, Madison, WI) or HaeIII (Promega); restriction fragments were analyzed
after 3% FingerPrinting agarose gel (BioAmerica Inc., Miami, FL) electrophore-
sis and staining with ethidium bromide. Fifty- and 25-bp DNA ladders (Promega)
were used as reference standards.
Species identification by DNA sequencing. At least one randomly selected
isolate from each of the 38 hospitals (74 isolates), as well as the isolate recovered
from the trocar, the unrelated strain, and isolates that presented distinct PRA-
hsp65 patterns were analyzed by the partial sequencing of the hsp65 and/or rpoB
genes, as previously described (2, 33).
Partial sequencing of the hsp65 gene. Primers hsp667FW (5-GGCCAAGAC
AATTGCGTACG-3) and hsp667RV (5-GGAGCTGACCAGCAGGATG-3)
were used to amplify and sequence a 667-bp region containing Telenti’s fragment
(positions 145 to 585 of the M. tuberculosis H37Rv genome) of the hsp65 gene.
A total of 5 l of each DNA solution (50 g/ml) was added to 45 l of a PCR
mixture containing 50 mM KCl, 20 mM Tris-HCl (pH 8.4), 1.5 mM MgCl2, 1%
enhancer (Invitrogen), 200 M each dNTP, 1 M primers, and 1.25 U of
Platinum Taq DNA polymerase (Invitrogen). Amplification conditions were 2
min at 95°C, followed by 30 cycles of 94°C for 45 s, 57°C for 45 s, and 72°C for
45 s, with a final extension step of 72°C for 5 min. Sequencing was performed as
described below.
Partial sequencing of the rpoB gene. A 764-bp fragment was amplified and
sequenced with primers MycoF (5-GCAAGGTCACCCCGAAGGG-3) and
MycoR (5-AGCGGCTGCTGGGTGATCATC-3). A total of 5 l of each
DNA solution (50 g/ml) was added to 45 l of a PCR mixture containing 50
mM KCl, 20 mM Tris-HCl (pH 8.4), 2.5 mM MgCl2, 200 M each dNTP, 1 M
primers, and 1.0 U of Taq DNA polymerase (Promega). PCR mixtures were
heated at 95°C for 1 min and then subjected to 35 cycles of denaturation at 94°C
for 30 s, annealing at 64°C for 30 s, and extension at 72°C for 90 s, with a final
step of 72°C for 5 min. Amplicons were purified with GFX PCR DNA and a Gel
Band purification kit (G&E) and sequenced in an ABI PRISM 3100 sequencer
with a BigDye Terminator cycle sequencing kit (Applied Biosystems). The se-
quences obtained were compared with those deposited in the GenBank database
by using BLAST (http://www.ncbi.nlm.nih.gov/BLAST).
Antimicrobial susceptibility testing. A total of 74 M. massiliense epidemic
isolates, including at least one from each hospital, previously identified to the
species level by hsp65 or rpoB gene sequencing were evaluated for their suscep-
tibility to amikacin, ciprofloxacin, cefoxitin, clarithromycin, and doxycycline as
recommended by the Clinical and Laboratory Standards Institute (10). Staphy-
lococcus aureus ATCC 29213 was used as a quality control strain.
Genomic restriction endonuclease digestion and PFGE. A total of 65 repre-
sentative isolates, including at least one isolate from each of the 38 hospitals that
had confirmed cases, isolates from previous M. massiliense outbreaks (F1345 and
F1832), and epidemiologically unrelated isolates (CRM-0270 and M. massiliense
type strain CIP108297) were analyzed by pulsed-field gel electrophoresis
(PFGE). Bacterial suspensions were included in agarose plugs, treated as de-
scribed by Coleman et al. (11) and Sampaio et al. (32), and finally digested with
DraI (Promega). Restriction fragments were separated by PFGE in 1% agarose
gels in a CHEF-DRIII system (Bio-Rad) with pulse times increasing from 1.6 to
21.3 s for 22 h at 14°C, with a voltage gradient of 6 V/cm. The restriction profiles
were analyzed and compared using the Molecular Analyst Fingerprinting Plus
software package, version 1.12, of the Image Analysis System (Bio-Rad). The
interpretative criteria applied were those proposed by Tenover et al. (37).
Glutaraldehyde tolerance. Five randomly selected isolates obtained from pa-
tients from hospitals H28 (CRM 0018, CRM 0019, and CRM 0020) and H34
(CRM 0034 and CRM 0035) belonging to the clonal group BRA100, as well as
two unrelated isolates cultivated from sputum samples (CRM 0270 and CRM
0273), were evaluated concerning their ability to survive after 30 min or 10 h of
exposure to 2% commercial glutaraldehyde solutions using the suspension
method, as recommended by the manufacturers for high-level disinfection and
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sterilization (6, 12). Each assay was repeated three times and also included
Mycobacterium smegmatis PRD no.1 00061, Mycobacterium bovis INCQS 00062,
M. abscessus ATCC 19977, and M. chelonae ATCC 35752 strains as quality
control strains. Mycobacterial suspensions with a turbidity equivalent to a Mc-
Farland 1 standard were prepared from cultures that had been grown on LJ
medium for no more than 7 days. Five hundred microliters was added to 4.5 ml
of each activated glutaraldehyde solution and incubated at 25°C. After 30 min
and 10 h, an aliquot of 0.5 ml of each mixture containing bacteria and glutaral-
dehyde was transferred to a new vial containing the same volume of 1% sodium
sulfite (1:1, vol/vol). They were mixed, seeded on LJ slants, and incubated at 35°C
in ambient air for 60 days.
Nucleotide sequence accession numbers. The GenBank database accession
numbers generated in this study are EU009467.1, EU009468.1 EU009469.1,
FJ515915.1, FJ515916.1, FJ516384.1, FJ516386.1, FJ531482.1, FJ531483.1, and
FJ531484.1.
RESULTS
Outbreak description and clinical findings. Among the
1,051 possible cases of postsurgery infections reported to the
Secretary of Health of Rio de Janeiro state between August
2006 and July 2007, 302 presented positive reported laboratory
tests. One hundred thirty were classified as probable cases, and
172 were considered confirmed cases (Fig. 1). Among the
confirmed cases, 148 isolates were available for further char-
acterization. Information regarding the gender and age of the
patient, type of surgery, surgeon name, and more were ob-
tained for 126 (86%) patients who had a positive culture for
mycobacteria. The most frequent type of surgery was cholecys-
tectomy (56.0%), followed by diagnostic laparoscopy (7.8%),
appendicectomy (7.1%), arthroscopy (5.5%), oophorectomy/
oophoroplasty (3.1%), hernioplasty (2.3%), tubal ligation
(2.3%), myomectomy (2.3%), gastroplasty (1.5%), rectosig-
moidectomy (1.5%), and other video-assisted procedures
(10.6%). The median age was 44 years old (range, 14 to 89),
and most patients (73.0%) were female. All patients had visible
cutaneous lesions (single or multiple), and most of them
(61.1%) presented serous, bloody, or purulent drainage from
infected wounds. Other clinical signs observed included ery-
thema (25.3%), subcutaneous nodules (23.0%), local pain
(21.4%), subcutaneous abscesses (19.8%), fever (11.1%),
edema (11.1%), fistulas (6.3%), and ulcers (3.9%). The median
time from surgery to the manifestation of clinical signs was 31
days (range, 2 to 187). A significant portion of the infections
(58.7%) occurred in patients that submitted to surgical proce-
dures at private institutions. A total of 38 hospitals, most of
them located around the urban area of the city of Rio de
Janeiro, had 1 to 15 confirmed cases of surgical site infection
caused by RGM.
The initial empirical treatment proposed by the federal
health authority included clarithromycin plus ethambutol and
terizidon or clarithromycin plus ethambutol and amikacin. As
soon as antimicrobial susceptibility tests and species identifi-
cation were available, ethambutol and terizidon were removed
from treatment regimens, and most of the patients were
treated with clarithromycin plus amikacin or clarithromycin
plus amikacin and imipenem or cefoxitin with good clinical
outcomes. Besides antimicrobial therapy, most of the patients
underwent surgical debridement and abscess drainage.
Commercial 2% glutaraldehyde solution was used for the
disinfection of the surgical instruments (15 to 30 min of expo-
sure) in all institutions that had confirmed cases. At least 58
different surgeons reported suspected cases during the epi-
demic period. From April 2008, no more cases have been
reported in the state of Rio de Janeiro. The decrease in the
number of cases was observed either after the discontinuation
of the use of 2% glutaraldehyde solution in high-level disin-
fection or during temporary interruptions of surgeries until the
resolution of epidemics at some care centers. No surveillance
studies were performed for mycobacterial isolation from med-
ical devices. No public health measures were suggested or
implemented by local authorities before September 2008.
Species identification. A total of 148 acid-fast-positive iso-
lates were recovered from clinical samples and available for
further characterization. Most of them (n  144; 97.2%) were
nonpigmented rapid growers, with a PRA-hsp65 pattern com-
patible with that of M. massiliense or M. bolletii (PRA-MmMb),
with BstEII restriction fragments of 235 and 210 bp and HaeIII
restriction fragments of 200, 70, 60, 50, and 40 bp (Fig. 2). All
isolates with the PRA-hsp65 pattern PRA-MmMb submitted
FIG. 1. Distribution of positive laboratory tests among 302 proba-
ble cases with notified laboratory diagnosis during the epidemic of
RGM postsurgical infections in Rio de Janeiro, Brazil (2006 to 2007).
FIG. 2. PRA-hsp65 profiles of six representative M. massiliense ep-
idemic isolates. Lanes 1 and 15, 50-bp DNA ladder; lane 8, 25-bp DNA
ladder; lanes 2 to 7, amplicons digested with BstEII; lanes 9 to 14,
amplicons digested with HaeIII. Each lane represents a different
strain: lane 2, CRM-0006; 3, CRM-0018; 4, CRM-0029; 5, CRM-0181;
6, CRM-0189; 7, CRM-0195; 9, CRM-0006; 10, CRM-0018; 11, CRM-
0029; 12, CRM-0181; 13, CRM-0189; and 14, CRM-0195.
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to sequencing (n  74) had identical rpoB sequences. Such
sequences (GenBank accession numbers EU009467.1,
EU009468.1, and EU009469.1) are 99.71% (686/688) similar
to those of the M. massiliense type strain CIP 108297
(EU254721.1 and AY593981.2). These two substitutions, lo-
cated at positions 2563 and 2754 of rpoB from M. tuberculosis
H37Rv (GenBank accession BX842574.1), are silent, since the
amino acid sequences are identical. Two (1.3%) nonpig-
mented, rapidly growing isolates presented identical PRA-
hsp65 patterns, with BstEII fragments of 230, 125, and 80 bp
and HaeIII fragments of 145, 120, 60, and 40 bp, which match
the patterns of the Mycobacterium fortuitum group. One of
these isolates (CRM-0264) had hsp65 and rpoB partial se-
quences that were identical to those of accession numbers
AY458072.1 and AY147165.1, respectively, which belong to
the type strain of M. fortuitum CIP104534. The second isolate
(CRM-0267) had hsp65 (GenBank accession no. FJ531484.1)
and rpoB (GenBank accession no. FJ531483.1) partial se-
quences that were 100% (424/424) and 99.56% (694/697)
similar to GenBank accession numbers AY458064.1 and
AY262743.2, respectively, which correspond to the Mycobac-
terium wolinskyi type strain ATCC700010. The two yellow-
pigmented scotochromogenic isolates F1672 and F1694 had
hsp65 partial sequences (GenBank accession numbers
FJ515915.1 and FJ515916.1) that had the highest similarity
indexes (99.8% [423/424] and 99.5% [422/424], respectively)
compared to the hsp65 sequence of the Mycobacterium neoau-
rum type strain CIP 105387 (GenBank accession no.
AF547860.1). Each of these M. neoaurum isolates were recov-
ered together with M. massiliense colonies from two patients
with mixed mycobacterial infection.
The unrelated isolate (CRM-0270) obtained from sputum
and the isolate cultivated from a trocar during the outbreak
period (CRM-0029) had rpoB sequences with the same simi-
larity indexes as those described above for the M. massiliense
epidemic isolates.
M. massiliense isolates from the outbreaks that occurred in
the cities of Goiaˆnia (F1345 and F1334; GenBank accession
nos. EU031904.1 and EU031905.1) and Bele´m (F1832;
GenBank accession no. FJ531482.1) had the same rpoB se-
quence as those described for the isolates from Rio de Janeiro.
Antimicrobial susceptibility. All 74 isolates tested were sus-
ceptible to amikacin (MIC at which 90% of the tested isolates
are inhibited [MIC90], 8 g/ml) and clarithromycin (MIC90,
0.25 g/ml) but resistant to ciprofloxacin and doxycycline. Ce-
foxitin MICs were high for most isolates (Table 1).
Clonal diversity. PFGE fingerprinting using DraI as the
restriction enzyme generated profiles with 12 or 13 fragments
without the use of thiourea in the running buffer. Clinical
isolates from the Rio de Janeiro epidemic and the isolate
cultivated from the trocar had identical PFGE patterns or
patterns that differed by a single fragment (Fig. 3 and 4). Their
PFGE patterns also were identical to those obtained for the
isolates from the previously reported outbreaks but differed
from PFGE patterns of the unrelated isolates CRM-0270 and
CIP 18297 (Fig. 4). The predominant clonal group was named
BRA100 to express its interhospital and interstate dissemina-
tion.
Glutaraldehyde tolerance. All five M. massiliense isolates
tested belonging to the clonal group BRA100 survived after 30
min and 10 h of exposure to 2% glutaraldehyde solution. Col-
onies were visible in LJ medium after 7 days. They were con-
firmed to be acid-fast bacilli and had the same PRA-hsp65
pattern as isolates exposed to 2% glutaraldehyde. M. smegma-
tis PRD no.1, M. bovis BCG INCQ 00062, M. abscessus ATCC
19977, M. chelonae ATCC 35752, and two unrelated M. mas-
siliense isolates (CRM-0270 and CRM-0273) did not survive
after 30 min of exposure.
DISCUSSION
This work reports the high frequency of a single clone of M.
massiliense associated with an epidemic of postsurgical infec-
tions caused by RGM. Although only five randomly chosen
isolates from this clonal group (BRA100) were tested, they
were reproducibly tolerant to 2% glutaraldehyde solution,
while controls and isolates not belonging to the epidemic clone
were not. This evidence suggests that glutaraldehyde tolerance
is a hallmark of the clonal group BRA100 and contributed to
the occurrence of the epidemic. Outbreaks due to RGM have
been detected in Brazil since 1998, but until 2004 none of them
was associated with a member of the M. abscessus group pre-
senting a PRA-hsp65 pattern that could correspond to M. mas-
FIG. 3. PFGE profiles of genomic DNA from M. massiliense iso-
lates after digestion with DraI. Lanes 1 and 15, molecular size markers
(Lambda DNA concatemers ranging from 48.5 to 1,018.5 kb); 2, CRM-
0006; 3, CRM-0013; 4, CRM-0018; 5, CRM-0019; 6, CRM-0020; 7,
CRM-0029; 8, CRM-0169, 9, CRM-0172; 10, CRM-0181; 11, CRM-
0185; 12, CRM-0189; 13, CRM-0191; and 14, CRM-0195.
TABLE 1. Antimicrobial susceptibility of 74 RGM M. massiliense
epidemic isolates recovered from wound infections after video
laparoscopic surgery during an outbreak in Rio de Janeiro,
Brazil (2006 to 2007)
Antimicrobial
agent
MIC (g/ml)
Range MIC50 MIC90
Amikacin 4–16 8 8
Cefoxitin 16–128 64 128
Ciprofloxacin 8–16 16 16
Clarithromycin 0.06–0.5 0.12 0.25
Doxycycline 16–32 32 32
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siliense or M. bolletii (5, 16, 30–32). The first two reports of
outbreaks associated with M. massiliense in Brazil recently
were published and describe surgical-site infections following
video-assisted surgeries that occurred in states other than Rio
de Janeiro (9, 40). The exact number of video-assisted proce-
dures performed monthly in Brazil is unknown, but this tech-
nology has been available in Brazil since 1990, and it is esti-
mated that 70% of abdominal surgeries currently are
performed using video equipment. No reports of infections
following video-assisted medical procedures had emerged be-
fore 2004 in Brazil. Postlaparoscopy infections caused by my-
cobacteria also have been described worldwide as isolated
cases or limited outbreaks (26, 27, 29, 41) and linked to pos-
sible sterilization pitfalls, as is probably the case in the present
epidemic. In this study, all hospitals that had cases of infections
due to M. massiliense used 2% alkaline glutaraldehyde solution
to disinfect surgical instruments that cannot be sterilized by
autoclaving, and this routine has long been employed. On the
other hand, some hospitals located in the state of Rio de
Janeiro that had used the same commercial glutaraldehyde
solutions have not had cases of surgical infections caused by
RGM to date. This may be explained by the well-known con-
cept that adequate mechanical cleaning may prevent biofilm
formation and bacterial adhesion (17). Our findings of a single
clone (BRA100) of glutaraldehyde-tolerant M. massiliense may
partially explain the occurrence of temporally clustered out-
breaks in three different regions in Brazil. Although biofilm
formation has been demonstrated to contribute to tolerance to
biocidal solutions (35), biofilm formation alone could not ex-
plain the occurrence of a single clone in three distant cities.
Two hypotheses arise from our observations: (i) this clone has
been spread in aquatic environments in Brazil for a long time,
FIG. 4. Dendrogram resulting from computer-assisted analysis of the PFGE profiles of 43 representative M. massiliense isolates. The Dice
coefficient was used for calculating the percentages of similarity among the profiles. M. massiliense isolates recovered during outbreaks in other
Brazilian cities are marked in bold. Diag., diagnosis. Footnotes: a, the mycobacterial isolate was recovered from a patient who submitted to video
laparoscopic surgery headed by the Dr.n team; b, the mycobacterial isolate was obtained from a patient who submitted to surgery at hospital (H) n;
c, RJ, Rio de Janeiro city; d, NR, not reported; e, NA, not applicable.
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and both the selective pressure of 2% glutaraldehyde use and
the inadequate mechanical cleaning of surgical instruments
have facilitated the occurrence of outbreaks, or (ii) this clone
was disseminated inside commercially available nonactivated
glutaraldehyde solutions, and the inadequate mechanical
cleaning of surgical instruments has facilitated the occurrence
of outbreaks. Some surgical teams carried their own instru-
ments and performed surgeries at different hospitals and even
different cities and states. The reuse of disposable or improp-
erly sterilized trocars by some of these teams also may have
contributed to the spread of a single clone and the large num-
ber of infected patients.
Our work, as with the two previous reports of M. massiliense
outbreaks, has a limitation; namely, the small number of un-
related strains and the unknown discriminatory power of
PFGE for this bacterial species. M. massiliense has phenotypic
and genotypic characteristics that are very similar to those of
M. abscessus. Although Ade´kambi et al. described some phe-
notypic tests (nitrate reductase, -glucuronidase, -galactosi-
dase, N-acetyl--glucosaminidase, and indole production) that
could differentiate these species, their conclusions were based
on two isolates and should not be applied to clinical laborato-
ries before validation with a large collection of unrelated iso-
lates (4). Although there is not a consensus on the best target
for mycobacterial species discrimination, the partial sequenc-
ing of hsp65 and/or rpoB genes has been used to differentiate
RGM species (2). Currently, species that have a similarity
index equal to or less than 98.1% for the rpoB fragment, as
proposed by Ade´kambi et al. (3), should be considered differ-
ent. In this work, we obtained the highest similarity index
(99.7%) for the comparison of our sequences to those of the
M. massiliense type strain. The hsp65 partial sequence of the
epidemic isolates had 100% similarity to that of the M. mas-
siliense type strain, while the minimal similarity index for the
same species has been proposed as 97% (21). These data
indicate that under the current classification of mycobacteria,
the epidemic was caused by M. massiliense.
In this report, all of the M. massiliense isolates tested were
susceptible to amikacin and clarithromycin but resistant to
cefoxitin, ciprofloxacin, and doxycycline. Our results are in
accordance with those reported by Ade´kambi et al. (4), except
that the doxycycline MICs for our isolates was higher, which is
in agreement with results reported by other authors (34, 40).
This evidence reinforces that susceptibility to doxycycline can-
not be used as a marker for differentiation between M. absces-
sus and M. massiliense.
In summary, to our knowledge, this report describes the
largest surgical-site infection epidemic caused by a unique
clone of M. massiliense reported to date and reinforces the risk
of using 2% glutaraldehyde solution for disinfecting surgical
devices.
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